Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Viatris is accelerating its transition toward innovative medicines with its October 8, 2026 agreement to acquire Pacira BioSciences (NASDAQ:PCRX) for approximately $1.65 billion in cash, or $36.50 per share.</li><li>The offer represents a roughly 45% premium to Pacira’s previous closing price and would add two established non-opioid pain therapies, EXPAREL and ZILRETTA, to Viatris’ pharmaceutical portfolio.</li><li>Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA during the twelve months ended June 2026, providing an existing earnings base rather than relying entirely on future drug launches.</li></ul>

Viatris is accelerating its transition toward innovative medicines with its October 8, 2026 agreement to acquire Pacira BioSciences (NASDAQ:PCRX) for approximately $1.65 billion in cash, or $36.50 per share.The offer represents a roughly 45% premium to Pacira’s previous closing price and would add two established non-opioid pain therapies, EXPAREL and ZILRETTA, to Viatris’ pharmaceutical portfolio.Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA during the twelve months ended June 2026, providing an existing earnings base rather than relying entirely on future drug launches.

Viatris’ Pacira Acquisition: Could $50 Million In Synergies Unlock Bigger Gains?